medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2005, Número 1

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2005; 3 (1)


Bleomicina intralesional en dermatología. Revisión

Hasson NA, Valdés FR, Murdoch VJ, Muñoz OC

Idioma: Español
Referencias bibliográficas: 38
Paginas: 15-21
Archivo PDF: 152.84 Kb.


RESUMEN

La bleomicina es una mezcla citotóxica de polipéptidos que ha sido usada tradicionalmente para el tratamiento sistémico de algunos cánceres. Por su alta selectividad por las células epiteliales se ha sugerido el uso de bleomicina intralesional para el tratamiento de ciertas patologías cutáneas.
En esta revisión se describe el uso de bleomicina intralesional para el tratamiento de verrugas, queloides, sarcoma de Kapósi, cáncer de piel no melanoma, leucoplaquia oral, hemangiomas y linfangiomas. Los resultados de los tratamientos son satisfactorios y prometedores para todas las lesiones, pero debido al escaso número de pacientes estudiados no se puede indicar como un método de rutina mientras no se disponga de mayor evidencia.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Umezawa H, Maeda K, Takeuchi T, Ishizuke M. New antibiotics, bleomycin A and B. J Antibiot A 1966; 19: 200-209

  2. Templeton S, Solomon A, Swerlick R. Intradermal bleomycin injections into Normal Human Skin. Arch Dermatol 1994; 130: 577-583

  3. Chabner B, Allegra C, Curt G, Calabresi P. “Antineoplastic agents”. In: Goodman and Gilman’s The pharmacological basis of therapeutics. 9th edition, McGraw Hill, New York, 1996

  4. Clayman G, Dreiling L. Inyectable modalities as local and regional strategies for head and neck cancer. Hematol Oncol Clin North Am 1999; 13 (4): 787-810

  5. James MP, Collier PM, Aherne W, Hardcastle A, Lovegrove S. Histologic, pharmacologic, and immunocytochemical effects to injection of bleomycin into viral warts. J Am Acad Dermatol 1993; 28: 933-937

  6. Warner D, Flowers F. Plasma levels of bleomycin after intralesional injection. J Am Acad Dermatol 1994; 29: 812

  7. Manz LA, Pelachyk JM. Bleomycin-lidocaine mixture reduces pain of intralesional injection in the treatment of recalcitrant verrucae. J Am Acad Dermatol 1991; 25: 524-526

  8. Sollito RJ, Napoli RC, Gazivoda PL, Hart TJ. A perspective study using bleomycin sulfate in the treatmente of plantar verrucae. J Foot Surg 1989; 28: 141-144

  9. Hayes ME, O’Keefe EJ. Reduced dose of bleomycin in the treatment of recalcitrant warts. J Am Acad Dermatol 1986; 15: 1002-1006

  10. Habif JA. “Warts”. In: Habif JA, Clinical Dermatology, 3th ed. Mosby- Yearbook Inc, New York, 1996, 326-334

  11. Munn SE, Higgins E, Marshall M, Clement M. A new method of intralesional bleomycin therapy in the treatment of recalcitrant warts. Br J Dermatol 1996; 135: 969-971

  12. Tsuji T. Bleomycin iontophoretic therapy for verrucous carcinoma. Arch Dermatol 1991; 127: 973-975

  13. Heller R, Jaroszeski M, Reintgen D, Puleo C, DeConti R, Gilbert R, Glass L. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 1998; 83: 148-157

  14. Rodríguez-Cuevas S, Barroso-Bravo S, Almarza-Estrada J, Cristóbal- Martínez L, González-Rodríguez E. Electrochemotherapy in primary and metastatic skin tumors: phase II trial using intralesional bleomycin. Arch Med Res 2001; 32: 273-276

  15. Glass F, Pepine M, Fenske N, Jaroszeski M, Reintgen D, Heller R. Bleomycin-mediated electrochemotherapy of metastatis melanoma. Arch Dermatol 1996; 132: 1353-1357

  16. Ota M, Kawashima M, Mitsuishi T. Multiple Bowen’s disease of the fingers. Eur J Dermatol 2002; 12: 275-277

  17. Silverman S Jr, Gorski M, Lozada F. Oral leukoplakia and malignant transformation. A follow up study of 257 patients. Cancer 1984; 53: 563-568

  18. Chu FWK, Silverman S Jr, Dedo HH. CO2 laser treatment of oral leukoplakia. Laryngoscope 1988; 98: 125-130

  19. Wong F, Epstein J, Millner A. Treatment of oral leukoplakia with topical bleomycin. Cancer 1989; 64: 361-365

  20. Epstein J, Gorski M, Wong F, Millner A. Topical bleomycin for the treatment of dysplastic oral leukoplakia. Cancer 1998; 83: 629-634

  21. Gascon P, Schwartz R. Kaposi´s sarcoma. Dermatol Clin 2000, 18 (1): 169-174

  22. O´Connor P, Scadden D. Aids Oncology. Infect Dis Clin North Am 2000, 14 (4): 945-965

  23. Poignonec S et al. Intralesional bleomycin for acquired immunodeficiency syndrome- associated cutaneous Kaposi’s sarcoma. Arch Dermatol 1995; 131: 228

  24. Boudreaux AA, Smith LL, Cosby CD et al. Intralesional vinblastine for cutaneous Kaposi’s sarcoma associated with acquired immunodeficiency syndrome. J Am Acad Dermatol 1993; 28: 61-65

  25. Shaffer J, Taylor S, Cook-Bolden F. Keloid scars: A review with a critical look at therapeutic options. J Am Acad Dermatol 2002; 46: S63-97

  26. España A, Solano T, Quintanilla E. Bleomycin in the treatment of keloids and hypertrophic scars by multiple needle punctures. Dermatol Surg 2001; 27 (1): 23-27

  27. Bodock I, Brun P. Treatment of keloid with intralesional bleomycin. Ann Dermatol Venereol 1996; 123 (12): 791-794

  28. Zheng QT. Local injection of Bleomycin A 5 in children with hemangiomas. Analysis of 210 cases. Zhonghua Wai Ke Za Zhi 1991; 29 (5): 290-291

  29. Sarihan H, Mocan H, Yildiz K, Abes M, Akyazici R. A new treatment with bleomycin for complicated cutaneous hemangioma in children. Eur J Pediatr Surg 1997; 7 (3): 158-162

  30. Kullendorff CM. Efficacy of bleomycin treatment for symptomatic hemangiomas in children. Pediatr Surg Int 1997; 12 (7): 526-528

  31. Orford J, Barker A, Thonell S, King P, Murphy J. Bleomycin therapy for cystic hygroma. J Pediatr Surg 1995; 30 (9): 1282-1287

  32. Miller RA. Nail dystrophy following intralesional injections of bleomycin for a periungueal wart. Arch Dermatol 1984; 120: 963-964

  33. Abess A, Keel D, Graham B. Flagellate hyperpigmentation following intralesional bleomycin treatment of verruca plantaris. Arch Dermatol 2003; 139: 337-339

  34. Smith EA, Harper FE, LeRoy EC. Raynaud’s phenomenon of a single digit following local intradermal bleomycin sulfate injection. Arthritis Rheum 1985; 28: 459-467

  35. Gregg LJ. Intralesional bleomycin and Raynaud’s phenomenon. J Am Acad Dermatol 1992; 26: 279-280

  36. Epstein E. Intralesional bleomycin and Raynaud’s phenomenon. J Am Acad Dermatol 1991; 24: 786-786

  37. Vanhootenghem O, Richert B, de la Brassinne M. Raynaud phenomenon after treatment verruca vulgaris of the sole with intralesional injection of bleomycin. Pediatr Dermatol 2001; 18: 249-251

  38. Allen A, Fosko S. Lymphangitis as a complication of intralesional bleomycin therapy. J Am Acad Dermatol 1998; 39: 295-297




2020     |     www.medigraphic.com